{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:04Z","timestamp":1786422724570,"version":"build-2736575974"},"reference-count":37,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen Medical Research Fund","award":["D2402020"],"award-info":[{"award-number":["D2402020"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573463"],"award-info":[{"award-number":["82573463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["82573463"],"award-info":[{"award-number":["82573463"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Hong Kong University Shenzhen Hospital Translational Medicine Centre","award":["HZQSWS-KCCYB-2024055"],"award-info":[{"award-number":["HZQSWS-KCCYB-2024055"]}]},{"name":"Shenzhen Science and Technology Program","award":["ZDSYS20210623091811035"],"award-info":[{"award-number":["ZDSYS20210623091811035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Immunotherapy has improved outcomes in non-small cell lung cancer (NSCLC), but reliable predictive biomarkers remain limited. DNA damage response (DDR) gene mutations may enhance tumor immunogenicity and response to immune checkpoint inhibitors (ICIs), yet clinical findings remain inconsistent. We aimed to systematically evaluate the association between DDR gene mutations and ICI outcomes in NSCLC. Methods: PubMed and Embase were searched for eligible studies. Data on objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were extracted and pooled using random-effects models. Subgroup analyses were performed by treatment regimen. Results: A total of 13 studies involving 5989 patients were included from 606 records. The pooled RR for ORR comparing DDR wild-type with DDR-mutated patients was 0.63 (95% CI: 0.49\u20130.82, p &lt; 0.001), indicating higher ORR in the DDR-mutated group. DDR mutations were also associated with improved PFS (HR = 0.56, 95% CI: 0.43\u20130.74, p &lt; 0.001) and OS (HR = 0.82, 95% CI: 0.68\u20130.98, p &lt; 0.05). In subgroup analyses, benefits were more consistent with ICI monotherapy, including improved PFS (HR = 0.59, 95% CI: 0.44\u20130.79, p &lt; 0.001) and ORR (RR = 0.60, 95% CI: 0.44\u20130.82, p = 0.001), while OS showed a nonsignificant trend. Evidence in the ICI-plus-chemotherapy subgroup remained inconclusive because of the limited number of available studies and substantial between-study heterogeneity. Conclusions: DDR gene mutations were associated with improved clinical outcomes in NSCLC patients treated with ICIs, particularly in the ICI monotherapy setting.<\/jats:p>","DOI":"10.3390\/cancers18162553","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:20:03Z","timestamp":1786324803000},"page":"2553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Mutations in DNA Damage Response Genes and Efficacy of Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Huixia","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Department of Clinical Oncology, The University of Hong Kong\u2013Shenzhen Hospital, Shenzhen 518053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing San","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Min","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-098X","authenticated-orcid":false,"given":"Feng-Ming (Spring)","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"Department of Clinical Oncology, The University of Hong Kong\u2013Shenzhen Hospital, Shenzhen 518053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: Progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients with Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"Kudaba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"17","author":"Schalper","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jtho.2024.04.011","article-title":"Pembrolizumab Plus Chemotherapy for Metastatic NSCLC with Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up","volume":"19","author":"Gadgeel","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","article-title":"Functional interrogation of DNA damage response variants with base editing screens","volume":"184","author":"Hayward","year":"2021","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40265-024-02066-9","article-title":"Targeting DNA Damage Response Deficiency in Thoracic Cancers","volume":"84","author":"Bzura","year":"2024","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib Monotherapy for Previously Treated Pancreatic Cancer with DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings from 2 Phase 2 Nonrandomized Clinical Trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer","volume":"27","author":"Peulen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1911895","DOI":"10.1001\/jamanetworkopen.2019.11895","article-title":"Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation with Response to Immune Checkpoint Inhibitors and Mortality in Patients with Non-Small Cell Lung Cancer","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-22-3413","article-title":"Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer","volume":"29","author":"Ricciuti","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102990","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"eBioMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, J., Tang, S., Zhang, C., Li, M., Zheng, Y., Hu, X., Huang, M., and Cheng, X. (2021). Investigation of PALB2 Mutation and Correlation with Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.742833"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.21037\/tlcr-22-746","article-title":"DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: A retrospective Chinese cohort study","volume":"11","author":"Xiao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/1759-7714.14902","article-title":"Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature","volume":"14","author":"Averbuch","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13000-023-01401-0","article-title":"DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy\/immunotherapy in advanced NSCLC patients","volume":"18","author":"Gu","year":"2023","journal-title":"Diagn. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.21873\/anticanres.16399","article-title":"Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer","volume":"43","author":"Kim","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Xiong, A., Nie, W., Zhou, Y., Li, C., Gu, K., Zhang, D., Chen, S., Wen, F., Zhong, H., and Han, B. (2021). Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.708558"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-023-01375-2","article-title":"POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"41","author":"Li","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","article-title":"Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Olivares-Hern\u00e1ndez, A., del Barco Morillo, E., Parra P\u00e9rez, C., Miramontes-Gonz\u00e1lez, J.P., Figuero-P\u00e9rez, L., Mart\u00edn-G\u00f3mez, T., Escala-Cornejo, R., Bellido Hern\u00e1ndez, L., Gonz\u00e1lez Sarmiento, R., and Cruz-Hern\u00e1ndez, J.J. (2022). Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020360"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e20232101","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-23-1122","article-title":"ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC","volume":"29","author":"Vokes","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jtho.2024.10.026","article-title":"The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC","volume":"20","author":"Gray","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: Lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:24:33Z","timestamp":1786422273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":37,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162553"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162553","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}